Comparison of patients with complete and partial biotinidase deficiency: biochemical studies.
Seventeen partially biotinidase-deficient patients detected by neonatal screening or family studies were compared with four patients with classical biotinidase deficiency. Using a sensitive HPLC method for biotinidase in plasma (substrate: biocytin) the patients could be divided into two groups: one with residual biotinidase activity, and the second with undetectable biotinidase activity (0-activity). Biocytin excretion, characteristically elevated in 0-activity patients, decreased rapidly with increasing residual biotinidase activity and was almost normal when residual activity exceeded 2-3% of mean normal. In one patient with classical disease (0-activity) biotin deficiency, typical organic aciduria and multiple carboxylase deficiency were found as early as at the second week of life. In contrast, 13 infants with residual activities from 1.2% to 23% had no remarkable clinical or biochemical abnormalities. However, in three 5-, 14- and 15-year-old healthy siblings with residual biotinidase activities between 2.3% and 4.2%, biotin deficiency was proven by decreased activities of the mitochondrial carboxylases in lymphocytes (30-57% of mean normal) and, in the older siblings, also by subnormal plasma biotin concentrations. In biotinidase deficiency, biotin depletion presumably occurs earlier in the brain than in other tissues and may thus first affect the central nervous system. For this reason and because of discrete biochemical abnormalities found in a patient with residual biotinidase activity of 8%, we suggest that at least all patients with residual activities below 10% should be treated with biotin.
Suormala
T M
TM
University Children's Hospital, Metabolic Unit, Basel, Switzerland.
Baumgartner
E R
ER
Wick
H
H
Scheibenreiter
S
S
Schweitzer
S
S
D000143:Acids / Q000378:metabolism; D000293:Adolescent; D000328:Adult; D000581:Amidohydrolases / Q000097:blood / Q000172:deficiency*; D001710:Biotin / Q000097:blood / Q000627:therapeutic use / Q000652:urine; D043523:Biotinidase; D002675:Child, Preschool; D005227:Fatty Acids / Q000378:metabolism; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008214:Lymphocytes / Q000201:enzymology; D008239:Lysine / Q000031:analogs & derivatives / Q000097:blood / Q000652:urine; D008297:Male; D008661:Metabolism, Inborn Errors / Q000188:drug therapy / Q000378:metabolism*; D009100:Multiple Carboxylase Deficiency / Q000378:metabolism
D000143:Acids; D005227:Fatty Acids; D001710:Biotin; D000581:Amidohydrolases; D043523:Biotinidase; C013411:biocytin; D008239:Lysine